132 related articles for article (PubMed ID: 36672477)
1. Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma.
Bloom EA; Peters PN; Whitaker R; Russell S; Albright B; Cummings S; Timms KM; Slavin T; Probst B; Strickland KC; Previs RA
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672477
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro D; Romero I; Pérez-Mies B; Redondo A; Caniego-Casas T; Carretero-Barrio I; Cristóbal E; Gutiérrez-Pecharromán A; Santaballa A; D'Angelo E; Hardisson D; Vieites B; Matías-Guiu X; Estévez P; Guerra E; Prat J; Poveda A; López-Guerrero JA; Palacios J
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446361
[TBL] [Abstract][Full Text] [Related]
3. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
4. Association between Tumor Mutational Burden, Stromal CD8
Ruan H; Oike T; Sato H; Ando K; Ohno T
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831552
[TBL] [Abstract][Full Text] [Related]
5. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
6. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
Li J; Wang J; Chen R; Bai Y; Lu X
Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
11. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
12. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab.
Lebow ES; Shepherd A; Eichholz JE; Offin M; Gelblum DY; Wu AJ; Simone CB; Schoenfeld AJ; Jones DR; Rimner A; Chaft JE; Riaz N; Gomez DR; Shaverdian N
JAMA Netw Open; 2023 Jan; 6(1):e2249591. PubMed ID: 36602799
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
15. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of tumor infiltrating lymphocytes in high-grade serous ovarian carcinoma].
Huang XM; Zhang Y; Xu L; Wang M; Wang W
Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):610-614. PubMed ID: 31422591
[No Abstract] [Full Text] [Related]
17. High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer.
Ölmez F; Oğlak SC; Ölmez ÖF; Akbayır Ö; Yılmaz E; Akgöl S; Konal M; Seyhan NA; Kinter AK
Turk J Obstet Gynecol; 2022 Sep; 19(3):246-256. PubMed ID: 36149309
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Shao C; Li G; Huang L; Pruitt S; Castellanos E; Frampton G; Carson KR; Snow T; Singal G; Fabrizio D; Alexander BM; Jin F; Zhou W
JAMA Netw Open; 2020 Oct; 3(10):e2025109. PubMed ID: 33119110
[TBL] [Abstract][Full Text] [Related]
19. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Hu-Lieskovan S; Lisberg A; Zaretsky JM; Grogan TR; Rizvi H; Wells DK; Carroll J; Cummings A; Madrigal J; Jones B; Gukasyan J; Shintaku IP; Slamon D; Dubinett S; Goldman JW; Elashoff D; Hellmann MD; Ribas A; Garon EB
Clin Cancer Res; 2019 Aug; 25(16):5061-5068. PubMed ID: 31113840
[TBL] [Abstract][Full Text] [Related]
20. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]